The Systemic Lupus Erythematosus Responder Index (SRI); A new SLE disease activity assessment

Autoimmunity Reviews

Volumn 11, Issue 5, 2012, Pages 326-329

  Luijten, K M A C ^a   Tekstra, J ^a   Bijlsma, J W J ^a   Bijl, M ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; PLACEBO;

BRITISH ISLES LUPUS ASSESSMENT GROUP; CLINICAL ASSESSMENT TOOL; DISEASE ACTIVITY; EUROPEAN CONSENSUS LUPUS ACTIVITY MEASUREMENT; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PHYSICIAN GLOBAL ASSESSMENT; REVIEW; SCORING SYSTEM; SYSTEMIC LUPUS ACTIVITY MEASURE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX; SYSTEMIC LUPUS ERYTHEMATOSUS RESPONDER INDEX; VISUAL ANALOG SCALE;

HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84857502011     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.06.011     Document Type: Review

References (38)

1. Westerweel P.E., Luyten R.K., Koomans H.A., Derksen R.H., Verhaar M.C. Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum 2007, 56(5):1384-1396.
2. Wollaston S.J., Farewell V.T., Isenberg D.A., Gordon C., Merrill J.T., Petri M.A., et al. Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group. J Rheumatol 2004, 31(12):2390-2394.
3. Mosca M., Tani C., Aringer M., Bombardieri S., Boumpas D., Brey R., et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 2010, 69(7):1269-1274.
4. Mosca M., Tani C., Aringer M., Bombardieri S., Boumpas D., Cervera R., et al. Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice. Autoimmun Rev 2011, 10(7):383-388.
5. Singh J.A., Christensen R., Wells G.A., Suarez-Almazor M.E., Buchbinder R., Lopez-Olivo M.A., et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Sao Paulo Med J 2010, 128(5):309-310.
6. Braus N.A., Elliott D.E. Advances in the pathogenesis and treatment of IBD. Clin Immunol 2009, 132(1):1-9.
7. Aringer M., Smolen J.S. Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus. Expert Opin Drug Saf 2008, 7(4):411-419.
8. Aringer M., Houssiau F., Gordon C., Graninger W.B., Voll R.E., Rath E., et al. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford) 2009, 48(11):1451-1454.
9. Merrill J.T., Burgos-Vargas R., Westhovens R., Chalmers A., D'Cruz D., Wallace D.J., et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010, 62(10):3077-3087.
10. Merrill J.T., Neuwelt C.M., Wallace D.J., Shanahan J.C., Latinis K.M., Oates J.C., et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010, 62(1):222-233.
11. Terrier B., Amoura Z., Ravaud P., Hachulla E., Jouenne R., Combe B., et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 2010, 62(8):2458-2466.
12. Stone J.H. BLISS! Lupus learns its lessons. Lancet 2011, 377(9767):693-694.
13. Griffiths B., Mosca M., Gordon C. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol 2005, 19(5):685-708.
14. Petri M., Genovese M., Engle E., Hochberg M. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum 1991, 34(8):937-944.
15. Petri M., Kim M.Y., Kalunian K.C., Grossman J., Hahn B.H., Sammaritano L.R., et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005, 353(24):2550-2558.
16. Petri M., Buyon J., Kim M. Classification and definition of major flares in SLE clinical trials. Lupus 1999, 8(8):685-691.
17. Symmons D.P., Coppock J.S., Bacon P.A., Bresnihan B., Isenberg D.A., Maddison P., et al. Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). Q J Med 1988, 69(259):927-937.
18. Yee C.S., Farewell V., Isenberg D.A., Griffiths B., Teh L.S., Bruce I.N., et al. The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. Rheumatology (Oxford) 2009, 48(6):691-695.
19. Isenberg D.A., Rahman A., Allen E., Farewell V., Akil M., Bruce I.N., et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005, 44(7):902-906.
20. Liang M.H., Socher S.A., Larson M.G., Schur P.H. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989, 32(9):1107-1118.
21. Bae S.C., Koh H.K., Chang D.K., Kim M.H., Park J.K., Kim S.Y. Reliability and validity of systemic lupus activity measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus. Lupus 2001, 10(6):405-409.
22. Ward M.M., Marx A.S., Barry N.N. Psychological distress and changes in the activity of systemic lupus erythematosus. Rheumatology (Oxford) 2002, 41(2):184-188.
23. Bombardier C., Gladman D.D., Urowitz M.B., Caron D., Chang C.H. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992, 35(6):630-640.
24. Hawker G., Gabriel S., Bombardier C., Goldsmith C., Caron D., Gladman D. A reliability study of SLEDAI: a disease activity index for systemic lupus erythematosus. J Rheumatol 1993, 20(4):657-660.
25. Gladman D.D., Ibanez D., Urowitz M.B. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002, 29(2):288-291.
26. Bencivelli W., Vitali C., Isenberg D.A., Smolen J.S., Snaith M.L., Sciuto M., et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992, 10(5):549-554.
27. Vitali C., Bencivelli W., Isenberg D.A., Smolen J.S., Snaith M.L., Sciuto M., et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. I. A descriptive analysis of 704 European lupus patients. European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992, 10(5):527-539.
28. Ward M.M., Marx A.S., Barry N.N. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. J Rheumatol 2000, 27(3):664-670.
29. Brunner H.I., Silverman E.D., Bombardier C., Feldman B.M. European Consensus Lupus Activity Measurement is sensitive to change in disease activity in childhood-onset systemic lupus erythematosus. Arthritis Rheum 2003, 49(3):335-341.
30. Doria A., Cutolo M., Ghirardello A., Zampieri S., Vescovi F., Sulli A., et al. Steroid hormones and disease activity during pregnancy in systemic lupus erythematosus. Arthritis Rheum 2002, 47(2):202-209.
31. Ehrenstein M.R., Conroy S.E., Heath J., Latchman D.S., Isenberg D.A. The occurrence, nature and distribution of flares in a cohort of patients with systemic lupus erythematosus: a rheumatological view. Br J Rheumatol 1995, 34(3):257-260.
32. Gordon C., Sutcliffe N., Skan J., Stoll T., Isenberg D.A. Definition and treatment of lupus flares measured by the BILAG index. Rheumatology (Oxford) 2003, 42(11):1372-1379.
33. Food and Drug Administration Guidance for industry systemic lupus erythematosus: developing drugs for treatment Available at:. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072063.pdf.
34. Furie R.A., Petri M.A., Wallace D.J., Ginzler E.M., Merrill J.T., Stohl W., et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009, 61(9):1143-1151.
35. Navarra S.V., Guzman R.M., Gallacher A.E., Hall S., Levy R.A., Jimenez R.E., et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011, 377(9767):721-731.
36. Wallace D.J., Stohl W., Furie R.A., Lisse J.R., McKay J.D., Merrill J.T., et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009, 61(9):1168-1178.
37. van der Heijde D.M., van 't H.M., van Riel P.L., van de Putte L.B. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993, 20(3):579-581.
38. Sostegni R., Daperno M., Scaglione N., Lavagna A., Rocca R., Pera A. Review article: Crohn's disease: monitoring disease activity. Aliment Pharmacol Ther 2003, 17(Suppl 2):11-17.